Rapid investigation of BA.4/BA.5 cases in France DOI Creative Commons

Alain-Claude Kouamen,

Helena Da Cruz,

Mohamed Hamidouche

и другие.

Frontiers in Public Health, Год журнала: 2022, Номер 10

Опубликована: Окт. 10, 2022

We aimed to describe the characteristics of individuals infected by BA.4 or BA.5 in France comparison BA.1, and analyze factors associated with hospitalization among cases. A standardized questionnaire was used collect information on confirmed probable Omicron Hospitalization risk BA.4/BA.5 cases were analyzed using Poisson regression. Variables a p-value below 0.2 univariate analysis priori confounders included multivariable regression model. The median age 301 investigated 47 years 97% symptomatic. most common clinical signs asthenia/fatigue (75.7%), cough (58.3%), fever headache (52.1%) rhinorrhea (50.7%). Twelve hospitalized, 27.1% reported factors. No admissions intensive care no deaths reported. Vaccination status available for 292 cases, 20.9% unvaccinated, 1.4% had received one dose, 38.3% two doses 39.4% three doses. Cases presenting at least factor almost seventeen times more likely be hospitalized than those (aRR = 16.72 [95% CI2.59-326.86]). Despite longer duration differences symptoms their possible immune escape, sub-lineages globally showed severe presentation. presence disease significantly increased BA.5.

Язык: Английский

A SARS-CoV-2: Companion Animal Transmission and Variants Classification DOI Creative Commons
Rachana Pandit, Qiana L. Matthews

Pathogens, Год журнала: 2023, Номер 12(6), С. 775 - 775

Опубликована: Май 29, 2023

The continuous emergence of novel viruses and their diseases are a threat to global public health as there have been three outbreaks coronaviruses that highly pathogenic humans in the span last two decades, severe acute respiratory syndrome (SARS)-CoV 2002, Middle East (MERS)-CoV 2012, SARS-CoV-2 which emerged 2019. unprecedented spread worldwide has given rise multiple variants either altered transmissibility, infectivity, or immune escaping ability, causing broad range animals including human non-human hosts such companion, farm, zoo, wild animals. In this review, we discussed recent outbreak, potential animal reservoirs, natural infections companion farm animals, with particular focus on variants. expeditious development COVID-19 vaccines advancements antiviral therapeutics contained pandemic some extent; however, extensive research surveillance concerning viral epidemiology, transmission, variants, seroprevalence diverse essential for future eradication COVID-19.

Язык: Английский

Процитировано

7
COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022 DOI
Lina Jeantin, Édouard Januel, Pierre Labauge

и другие.

Multiple Sclerosis Journal, Год журнала: 2024, Номер 30(3), С. 381 - 395

Опубликована: Янв. 21, 2024

Background: Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused the first waves of pandemic until early 2021. Objectives: We aimed to extend these data from onset global coverage by vaccination summer 2022. Methods: This retrospective, multicenter observational study analyzed COVISEP registry reported COVID-19 cases pwMS between January 2020 and July Severe was defined as hospitalization or higher severity. Results: Among 2584 confirmed/highly suspected COVID-19, severe infection rates declined 14.6% preomicron wave 5.7% during omicron ( p < 0.001). Multivariate analysis identified age (odds ratio (OR) = 1.43, 95% confidence interval (CI) [1.25–1.64] per 10 years), male sex (OR 2.01, CI [1.51–2.67]), obesity 2.36, [1.52–3.68]), cardiac comorbidities [1.46–3.83]), Expanded Disability Status Scale (EDSS) scores 2.09, [1.43–3.06] for EDSS 3–5.5 OR 4.53, [3.04–6.75] ⩾6), anti-CD20 therapies 2.67, [1.85–3.87]) risk factors Vaccinated individuals experienced less whether (risk (RR) 0.64, [0.60–0.69]) off (RR 0.32, [0.30–0.33]) anti-CD20. Discussion: In pwMS, consistent were neurological disability, emerging vital drivers severity regardless wave, period, status.

Язык: Английский

Процитировано

2
Clinical characteristics of COVID‐19 patients infected by the Omicron variants in Macao, China: A cross‐sectional study DOI Creative Commons
Hou Hon Cheong,

Fong I Sio,

Chi Chung Chan

и другие.

Health Science Reports, Год журнала: 2023, Номер 6(7)

Опубликована: Июль 1, 2023

Abstract Background and Aims The evolving mutants of SARS‐CoV‐2 have made the COVID‐19 pandemic sustained for over 3 years. In 2022, BA.4 BA.5 were Omicron variants dominating spread globally. Although was no longer a Public Health Emergency International Concern (PHEIC) as announced by WHO, remain challenge to global healthcare under circumstances withdrawal loosening personal protective behavior in post‐quarantine era. This study aims acknowledge clinical characteristics caused BA.4/BA.5 naive people analyze possible factors affecting disease severities. Methods this retrospective study, we report features 1820 patients infected with during local outbreak that occurred Macao SAR, China, from June July 2022. Results A total 83.5% symptomatic eventually. most common symptoms fever, cough, sore throat. Hypertension, dyslipidemia, diabetes mellitus leading comorbidities. There significantly more elderly ( p < 0.001), comorbidity 0.001) without vaccination or not completing series “Severe Critical” group. All deceased at least three comorbidities partial totally dependent their daily lives. Conclusion Our data are consistent milder BA.4/5 general population, while old age developed severe critical diseases. Complete booster doses effective strategies reinforce protection against diseases avoid mortality.

Язык: Английский

Процитировано

5
Comparison of Clinical Outcomes and Imaging Features in Hospitalized Patients with SARS-CoV-2 Omicron Subvariants DOI
Jong Eun Lee, Minhee Hwang, Yun‐Hyeon Kim

и другие.

Radiology, Год журнала: 2023, Номер 308(1)

Опубликована: Июль 1, 2023

Background Differences in the clinical and radiologic characteristics of SARS-CoV-2 Omicron subvariants have not been well studied. Purpose To compare disease severity radiologically severe pneumonia patients with COVID-19 who were hospitalized during a period either BA.1 BA.2 or BA.5 subvariant predominance. Materials Methods This multicenter retrospective study included registered Korean Imaging Cohort database for from January to December 2022. Publicly available relative variant genome frequency data used determine dominant periods (January 17 June 20, 2022) (July 4 5, 2022). Clinical outcomes imaging based on chest radiography CT compared between predominant groups using multivariable analyses adjusted covariates. Results Of 1916 confirmed (mean age, 72 years ± 16 [SD]; 1019 male), 1269 predominance (BA.1/BA.2 group) 647 (BA.5 group). Patients group showed lower odds high-flow O2 requirement (adjusted ratio [OR], 0.75 [95% CI: 0.57, 0.99]; P = .04), mechanical ventilation OR, 0.49 0.34, 0.72]; < .001]), death 0.47 0.33, 0.68]; .001) than those BA.1/BA.2 group. Additionally, had radiographs 0.68 0.53, 0.88]; .004) higher "atypical" pattern images 1.81 1.26, 2.58]; Conclusion predominance, even after adjusting © RSNA, 2023 Supplemental material is this article. See also editorial by Hammer issue.

Язык: Английский

Процитировано

5
Rapid investigation of BA.4/BA.5 cases in France DOI Creative Commons

Alain-Claude Kouamen,

Helena Da Cruz,

Mohamed Hamidouche

и другие.

Frontiers in Public Health, Год журнала: 2022, Номер 10

Опубликована: Окт. 10, 2022

We aimed to describe the characteristics of individuals infected by BA.4 or BA.5 in France comparison BA.1, and analyze factors associated with hospitalization among cases. A standardized questionnaire was used collect information on confirmed probable Omicron Hospitalization risk BA.4/BA.5 cases were analyzed using Poisson regression. Variables a p-value below 0.2 univariate analysis priori confounders included multivariable regression model. The median age 301 investigated 47 years 97% symptomatic. most common clinical signs asthenia/fatigue (75.7%), cough (58.3%), fever headache (52.1%) rhinorrhea (50.7%). Twelve hospitalized, 27.1% reported factors. No admissions intensive care no deaths reported. Vaccination status available for 292 cases, 20.9% unvaccinated, 1.4% had received one dose, 38.3% two doses 39.4% three doses. Cases presenting at least factor almost seventeen times more likely be hospitalized than those (aRR = 16.72 [95% CI2.59-326.86]). Despite longer duration differences symptoms their possible immune escape, sub-lineages globally showed severe presentation. presence disease significantly increased BA.5.

Язык: Английский

Процитировано

8